Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Histologic diagnosis of unresectable stage III or IV metastatic melanoma
Prior ipilimumab induction treatment (3 mg/kg)
Documented disease control \[Stable Disease ≥3 months or Partial Response/Complete Response\] after ipilimumab induction
Documented progressive disease following disease control
You may not be if
Patients with brain metastasis are excluded, unless they are free of neurologic symptoms related to metastatic brain lesions and do not receive systemic corticosteroid therapy for the purpose of reducing intracranial inflammation in the 10 days prior to beginning retreatment with ipilimumab
Any intervening anticancer therapy between last dose of ipilimumab induction and ipilimumab retreatment on study
Patients who experienced any grade 3 immune-related adverse event (irAE) (except for endocrinopathies where clinical symptoms were controlled with appropriate hormone replacement therapy) or any grade 4 toxicity during prior treatment with ipilimumab
Patients with a prior irAE that has not improved to grade 1 or better at randomization
Clareo Health | Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
